TA 46

Drug Profile

TA 46

Alternative Names: TA-46

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Therachon
  • Class Growth hormones; Proteins
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Achondroplasia

Most Recent Events

  • 05 Jan 2017 Preclinical trials in Achondroplasia in Switzerland (unspecified route)
  • 01 Dec 2016 Early research in Achondroplasia in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top